Nyrada Doses First Patient in Phase 2a Trial of Heart Attack Drug Candidate
() -- Nyrada (ASX:NYR) has initiated its PROTECT-MI phase 2a clinical trial with the dosing of the first patient evaluating its transient receptor potential canonical ion channel inhibitor Xolatryp, according to a Monday filing with the Australian bourse. The trial is a randomized, double-blind, placebo-controlled stud